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Abstract
Objective—Investigate relationships between early blood pressure (BP) changes, receipt of anti-
hypotensive therapy, and 18 – 22 month corrected age (CA) outcomes for extremely preterm 
infants.
Design—Prospective observational study of infants 230/7 – 266/7 weeks gestational age (GA). 
Hourly BP values and anti-hypotensive therapy exposure in the first 24 hours were recorded. Four 
groups were defined: infants who did or did not receive anti-hypotensive therapy in whom BP did 
or did not rise at the expected rate (defined as an increase in the mean arterial BP of ≥5 mmHg/
day). Random-intercept logistic modeling controlling for center clustering, GA, and illness 
severity was used to investigate the relationship between BP, anti-hypotensive therapies, and infant 
outcomes.
Setting—Sixteen academic centers of the Eunice Kennedy Shriver National Institute of Child 
Health and Human Development Neonatal Research Network.
Main Outcome Measures—Death or neurodevelopmental impairment / developmental delay 
(NIDD) at 18 – 22 months CA.
Results—Of 367 infants, 203 (55%) received an anti-hypotensive therapy, 272 (74%) survived to 
discharge, and 331 (90%) had a known outcome at 18 – 22 months CA. With logistic regression, 
there was an increased risk of death/NIDD with anti-hypotensive therapy versus no treatment 
(odds ratio: 1.836, 95% confidence interval: 1.092 – 3.086), but not NIDD alone (odds ratio: 1.53, 
95% confidence interval: 0.708 – 3.307).
Conclusion—Independent of early BP changes, anti-hypotensive therapy exposure was 
associated with an increased risk of death/NIDD at 18 to 22 months CA when controlling for risk 
factors known to affect survival and neurodevelopment.
Keywords
Extremely preterm infant; blood pressure; neurodevelopment; hypotension
INTRODUCTION
Many investigations in the last 25 years suggest preterm infants considered hypotensive in 
the immediate postnatal period are at increased risk for adverse outcomes.1-14 This 
observation has led some clinicians to administer therapies in an effort to raise arterial blood 
pressure (BP) and, presumably, improve an infant’s chances of survival without major 
morbidity.12-16 To date, no such improvement in outcomes has been observed.1-16 More 
concerning is the possibility that commonly prescribed anti-hypotensive therapies may 
increase risks to preterm infants.3,7, 12-14
The evolving physiology of extremely preterm infants and the dynamic nature of the 
cardiovascular system are some of the inherent challenges to investigating BP management 
in the immediate newborn period. The wide range of BP values observed at any given 
postnatal hour and the spontaneous rise in BP which typically occurs after birth5,8,9 make it 
difficult to determine whether a BP value for a given infant at a specific postnatal age is too 
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high, too low, rising too quickly, or not increasing quickly enough. There are no placebo-
controlled randomized trials to guide therapeutic decisions.3,17-19 As such, BP management 
for this population varies considerably with a wide range in the frequency of anti-
hypotensive therapy administration for perceived low BP.12-14,16
Data on the relationship between early BP management and neurodevelopmental 
impairment / developmental delay (NIDD) are insufficient and difficult to interpret. This is 
related in part to the limited number of studies reporting rates of NIDD, patient sample sizes, 
data on specific anti-hypotensive therapies, and heterogeneous study populations.9-11 
Perhaps most importantly, previous investigations did not account for the spontaneous rise in 
BP that occurs after birth in preterm infants.5,8,9 As a result, it is difficult to determine 
whether infant outcomes after the administration of anti-hypotensive therapies are related to 
BP increasing in conjunction with therapy. The objectives of this study were to evaluate 
toddler age outcomes in a cohort of extremely preterm infants divided into groups defined 
by early changes in BP and receipt of anti-hypotensive therapy in an effort to clarify: 1) 
whether adverse outcomes in infants with a concerning BP are related to lack of anti-
hypotensive therapy administration and; 2) whether survival and / or intact 
neurodevelopment in treated infants are related to a rise in BP.
METHODS
This study reports the outcomes at 18 to 22 months corrected age (CA) for infants enrolled 
in a prospective observational study of inborn extremely preterm infants born at 230/7 to 
266/7 weeks gestational age (GA) at 16 academic centers of the Eunice Kennedy Shriver 
National Institute of Child Health and Human Development Neonatal Research Network 
(NRN) enrolled from July 21, 2010 to January 21, 2011. A detailed description of the patient 
population, explanation of the informed consent process, and in-hospital outcomes have 
been reported previously.8,14 Briefly, hourly BP measurements (both invasive and non-
invasive) and the administration of all anti-hypotensive therapies in the first 24 hours were 
recorded. Anti-hypotensive therapy included a fluid bolus (≥10 ml/kg of crystalloid), 
dopamine, dobutamine, hydrocortisone, epinephrine, or any blood product. All treatment 
decisions were made by the clinical care team. Inborn infants born at 23 through 26 weeks 
GA admitted to the neonatal intensive care unit were included in this study. Infants were 
excluded if they died in the delivery room, had a major birth defect, or had intensive care 
withheld or withdrawn shortly after birth because the clinical care team felt the situation was 
hopeless. This study was approved by the Institutional Review Board of each participating 
center. At two centers, infants were enrolled after parents signed a study specific informed 
consent form. At the remaining 14 centers, this study was incorporated into the ongoing 
Generic Database (GDB) study of the NRN because all infants in this study qualified for 
GDB enrollment (on the basis of their GA at birth) and both studies collected de-identified 
patient information. The Institutional Review Board of some NRN centers allowed for GDB 
data collection with a waiver of consent.8
The primary outcome for this investigation was the incidence of death or NIDD at 18 to 22 
months CA. Neurodevelopmental impairment or developmental delay was defined as a 
Bayley Scales of Infant Development, Third Edition20 cognitive or motor score < 70, 
Batton et al. Page 3
Arch Dis Child Fetal Neonatal Ed. Author manuscript; available in PMC 2016 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
cerebral palsy (Gross Motor Function Classification System level greater than two),21 
hearing impairment requiring hearing aids in both ears, or blindness (some or no useful 
vision in either eye). Secondary outcomes were the rates of any NIDD and individual 
components of NIDD among infants who survived to 18 – 22 months CA. Outcomes were 
compared among four infant groups defined by the administration of anti-hypotensive 
therapy and the rate of rise in BP: 1) infants who did not receive an anti-hypotensive therapy 
in whom the BP rose as expected; 2) untreated infants in whom BP did not rise at the 
expected rate; 3) infants who received an anti-hypotensive therapy in the first 24 hours in 
whom BP rose as expected and; 4) treated infants who did not experience the expected rise 
in BP. The expected rise in BP was defined a priori as an increase in the mean arterial BP of 
≥ 5 mmHg from postnatal hour four to postnatal hour 24. This definition was chosen 
because this rate of rise was reported previously for extremely preterm infants, this was the 
average rate of rise in mean arterial BP for this cohort of infants, the average rate of rise was 
the same for each week gestation across this GA range, and the average rate of rise for this 
cohort was the same for infants who did versus did not receive an anti-hypotensive 
therapy.5,8
Data analysis was performed at the NRN Data Coordinating Center (RTI International, 
Research Triangle Park, NC). Statistical analysis was performed using SAS 9.3 software 
(SAS Institute Inc., Cary, NC). For univariable analysis, Chi-squared or Fisher’s exact tests 
were used for comparison of proportions and Analysis of Variance was used for comparison 
of means. Logistic regression models that included a random intercept to account for 
potential center clustering were estimated for the outcomes of death / NIDD and NIDD 
(alone). Infant-level covariates of GA at birth and severity of illness were used as covariates, 
in addition to anti-hypotensive therapy exposure (treated versus untreated) and early changes 
in BP (expected rate of rise versus less than the expected rate of rise).14 Severity of illness 
was defined as the cumulative number of any of the following: a one minute Apgar score 
less than or equal to three, presence of early anemia (an initial hematocrit ≤ 30%), any pH < 
7.10 in the first 24 hours after birth, a positive early blood culture (drawn within 72 hours of 
birth), or delivery room chest compressions.14
RESULTS
There were 367 infants enrolled in the study (Figure 1). Of these, 158 infants survived the 
first 24 hours without receiving an anti-hypotensive therapy, including 91 (58%) in whom 
the mean arterial BP increased by ≥ 5 mmHg and 67 (42%) infants in whom it did not. 
Blood pressure rose as expected for 128 (65%) of the 198 infants who received an anti-
hypotensive therapy. Of the 203 infants who received an anti-hypotensive therapy, 135 
(67%) received a fluid bolus, 102 (50%) received a blood product, and 92 (45%), 25 (12%), 
18 (9%), and one (<1%) received dopamine, hydrocortisone, dobutamine, and vasopressin, 
respectively. Five infants who received an anti-hypotensive therapy died in the first 24 hours. 
In-hospital variables and outcome data for the four infant cohorts are presented in Table 1.
Eighteen to 22 month CA outcomes (death or neurodevelopmental assessment) were known 
for 331 (90%) infants. This included 99 infants who died and 232 infants who underwent 
neurodevelopmental testing. Thirty-six infants were lost to follow-up. There were not any 
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significant differences in known in-hospital morbidities or therapies between infants lost to 
follow-up and hospital survivors with known 18 – 22 month outcomes. On univariable 
analysis, death or NIDD was significantly higher in treated infants as compared to untreated 
infants (Table 2) irrespective of whether BP rose as expected. The rates of individual 
components of NIDD varied across the four groups, but these differences did not reach 
statistical significance (Table 2; p > 0.05 for each).
There were significant differences in the incidence of NIDD or the composite outcome of 
death/NIDD from random-effects logistic regression models (table 3). For each one week 
increase in GA at birth, both the likelihood of NIDD or death/NIDD decreased. The 
presence of any marker of severity of illness increased the odds of both NIDD and death/
NIDD as did the cumulative number of severity of illness markers. When incorporating these 
variables and changes in BP into regression models, treatment with any anti-hypotensive 
therapy was a significant predictor of death/NIDD, but not NIDD alone. In similar 
regression models incorporating anti-hypotensive treatment, the rise in BP (at the expected 
rate versus less than the expected rate) was not significantly associated with either outcome.
DISCUSSION
Previous studies examining the relationship between early BP management and infant 
outcomes either evaluated hypotensive infants versus normotensive infants or infants with 
treated versus untreated hypotension.6,9-11 Hypotension was defined as either receipt of an 
anti-hypotensive therapy (irrespective of BP values) or a BP value below a numeric 
threshold (e.g. a mean arterial BP less than or equal to the numerical equivalent of the 
infant’s GA) which was not necessarily used clinically. Difficulties with investigating early 
BP management include the spontaneous rise in BP that occurs after birth, the positive 
correlation between BP values and GA at birth, and the wide range in BP values observed at 
any specific postnatal hour for infants at all GA ranges.5,6,8 The findings of this study 
underscore the importance of considering multiple factors when examining BP in relation to 
infant outcomes.
Infants given an anti-hypotensive therapy had a higher rate of death / NIDD irrespective of 
early BP changes. The significance of this finding remains unclear. It is possible parameters 
other than a numeric threshold for low BP may better identify infants at risk for a poor 
outcome who would benefit from therapy. Incorporation of indirect measures of systemic or 
cerebral blood flow may also partially explain the observed variability in BP management, 
including why some infants without low BP received an anti-hypotensive therapy while 
other infants with low BP did not.3,14,22,23
Although not statistically significant (p = 0.055), there was a trend towards higher mortality 
in treated infants (29%) versus untreated infants (17%) in this study, irrespective of the BP 
rate of rise. Other reports have also suggested that infants who receive an anti-hypotensive 
therapy have a higher mortality rate.5-7,24 Definitive conclusions regarding this association 
cannot be made since to date there are no randomized trials. Potential confounders include 
higher illness severity in treated infants, a greater likelihood of a condition known to 
increase mortality (e.g. sepsis), inclusion of infants in extremis who received an anti-
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hypotensive therapy but were likely to die irrespective of the degree of therapeutic support 
provided, and omission of other factors which may predispose an infant to both perceived 
low BP requiring intervention and death (such as a low Apgar score or early acidosis). 
Attempts were made to control for these concerns in the current study such as excluding 
infants deemed terminally ill in the first 24 hours and incorporating severity of illness into 
the regression analyses using factors which both impact BP management and are associated 
with lower survival.14
In a previous multi-center study, the ELGAN Study investigators evaluated the relationship 
between indicators of hypotension and rates of NIDD at 24 months CA.9 Similar to this 
study, those investigators found little evidence of an association between early BP values 
and subsequent neurodevelopment. Other studies report similar findings.10,11,18 The 
association between anti-hypotensive therapy and hearing loss reported by Fanaroff et al was 
not observed in this investigation, possibly due to the low rate of deafness overall (less than 
three percent).6
Data from this study and others demonstrate the complex relationship between early blood 
pressure management, mortality, and neurodevelopment. Death and NIDD are distinct 
outcomes and it is likely that circumstances which lead to death are distinct from but overlap 
with factors which lead to brain injury such that these therapies – or factors influencing the 
decision to administer them – may influence mortality risk differently than they influence 
the risk of NIDD.25,26 Alternatively, factors beyond the immediate postnatal period may 
have more influence on toddler age outcomes thus masking the impact of early BP 
management on neurodevelopment.25 Lastly, given the complexity of the immature 
cardiovascular system, anti-hypotensive therapies may inconsistently influence cardiac 
function such that they do not uniformly alter early postnatal cerebrovascular blood flow or 
oxygen delivery.18,22,23
Study strengths include consistent prospective data collected by trained research personnel, 
inclusion of a large multicenter population of extremely preterm infants, analysis based on 
GA rather than birth weight, and systematic assessment of neurodevelopment by examiners 
masked to the infant’s early BP management who were trained in the standardized 
administration of the Bayley Scales of Infant Development, Third Edition. Importantly, this 
study may have been underpowered to demonstrate statistically significant, but clinically 
relevant, differences in some infant outcomes. Additional study limitations reported 
previously include the observational study design, a lack of data for some variables that may 
have contributed to BP management decisions, variability in infant enrollment across NRN 
centers, and inconsistency in how BP values were obtained.14 There was substantial 
heterogeneity in the treatment of perceived low BP and this also may limit applicability of 
the study findings.
CONCLUSIONS
Extremely preterm infants who received an anti-hypotensive therapy in the first 24 hours 
after birth had a significantly higher rate of death or impaired neurodevelopment at 18 – 22 
months CA than untreated infants irrespective of early changes in BP. These results cannot 
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be explained by differences in the markers of illness severity collected for this study which 
include factors known to impact infant survival and morbidity. There is limited evidence to 
suggest anti-hypotensive therapies improve outcomes for preterm infants and growing 
concern these therapies may be harmful. It is possible therapeutic interventions for perceived 
low BP increase the risk of adverse outcomes in extremely preterm infants.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
• Extremely preterm infants who receive anti-hypotensive therapies have worse 
in-hospital outcomes.
• The relationship between toddler age outcomes, early blood pressure values, and 
anti-hypotensive therapies is unclear.
• Investigating these relationships is challenging in part because of changes in 
blood pressure values occurring shortly after birth.
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WHAT THIS STUDY ADDS
• Infants who received an anti-hypotensive therapy were more likely to have an 
adverse outcome at 18 to 22 months corrected age than untreated infants 
irrespective of whether or not blood pressure increased.
• These results cannot be explained by differences in the markers of severity of 
illness investigated.
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Figure 1. 
Extremely preterm infant study enrollment classified by study group; NICU = neonatal 
intensive care unit; BP = blood pressure; ND = neurodevelopmental
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Table 1
In-hospital variables & outcomes for infants based on receipt of anti-hypotensive therapy & rise in blood 
pressure
Untreated
expected
BP rise
(n=91)
Untreated
less than expected
BP rise
(n=67)
Treated
expected
BP rise
(n=128)
Treated
less than expected
BP rise
(n=70) p-value
Birth weight (grams), mean ± SD 784 ± 165 750 ± 144 692 ± 150 713 ± 168 <0.001
GA at birth (weeks), mean ± SD 25.5 ± 0.9 25.6 ± 1.0 25.1 ± 1.1 25.3 ± 1.0 <0.001
Antenatal corticosteroids, # (%) 81 (89) 61 (91) 118 (92) 65 (93) 0.814
Any severity of illness marker, # (%)
 1 minute Apgar score ≤ 3
 DR chest compressions
 Positive initial blood culture
 Any pH <7.10 in the 1st 24 hours
 First hematocrit <30%
37 (41)
33 (36)
5 (5)
0
1 (1)
4 (4)
37 (55)
33 (49)
7 (10)
0
3 (4)
3 (4)
93 (73)
79 (62)
14 (11)
3 (2)
13 (10)
25 (20)
56 (80)
49 (70)
8 (11)
5 (7)
11 (16)
12 (17)
<0.001
<0.001
0.5
0.01¶
0.003
<0.001
Severe IVH or PVL, # (%) 11 (12) 8 (13) 28 (23) 21 (31) 0.008
NEC requiring surgery, # (%) 4 (5) 2 (4) 6 (7) 2 (4) 0.881¶
Intervention for ROP, # (%) 9 (12) 6 (11) 18 (20) 14 (27) 0.071
BPD, # (%) 40 (51) 36 (63) 58 (62) 34 (62) 0.402
Survival to hospital discharge 77 (85) 54 (81) 89 (70) 52 (74) 0.055
BP = blood pressure; ANOVA = analysis of variance; SD = standard deviation; GA = gestational age; DR = delivery room; IVH = intraventricular 
hemorrhage; PVL = periventricular leukomalacia; NEC = necrotizing enterocolitis; ROP = retinopathy of prematurity; BPD = bronchopulmonary 
dysplasia
¶
Fisher's Exact Test
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Table 2
Outcomes at 18 – 22 months for infants based on receipt of anti-hypotensive therapy & rise in blood pressure
Untreated
expected
BP rise
(n=91)
Untreated
less than expected
BP rise
(n=67)
Treated
expected
BP rise
(n=128)
Treated
less than expected
BP rise
(n=70) p-value
Death or any ND impairment/delay, # (%) 24 (26) 19 (28) 58 (45) 33 (47) 0.002
*Any ND impairment/delay, # (%) 9 (14) 6 (12) 16 (23) 14 (30) 0.079
Language composite score, mean ± SD 86 ± 16 87 ± 13 84 ± 17 83 ± 18 0.531
Cognitive composite score, mean ± SD 91 ± 14 90 ± 10 86 ± 17 88 ± 17 0.33
Motor composite score, mean ± SD 89 ± 15 89 ± 12 86 ± 17 86 ± 18 0.53
*Language composite score < 70, # (%) 8 (12) 2 (4) 13 (19) 9 (19) 0.081
*Cognitive composite score <70, # (%) 5 (8) 1 (2) 11 (16) 7 (15) 0.0554
*Motor composite score <70, # (%) 7 (11) 4 (8) 10 (14) 10 (21) 0.162
*GMFCS level ≥2, # (%) 4(6) 4(8) 9 (13) 8 (17) 0.251
*Blindness, # (%) 1 (2) 0 0 0 0.697¶
*Deafness, # (%) 1 (2) 1 (2) 1 (1) 3 (6) 0.426¶
BP = blood pressure; ANOVA = analysis of variance; ND = neurodevelopment; SD = standard deviation; GMFCS = Gross Motor Function 
Classification System;
*denominator is infants who had a neurodevelopmental assessment at 18 – 22 months corrected age
¶
Fisher's Exact Test
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Table 3
Estimation results from Logistic regression models with a random intercept
Covariate
NIDD Death / NIDD
Odds
Ratio
95%
Confidence Interval
Odds
Ratio
95%
Confidence Interval
Each one week increase in GA at birth 0.688 0.479 – 0.988 0.608 0.476 – 0.777
Presence of any marker of severity of illness* 2.733 1.123 – 6.652 1.872 1.074 – 3.261
Higher cumulative number of severity of illness markers 2.065 1.275 – 3.346 1.672 1.204 – 2.322
Any anti-hyotensive therapy treatment 1.53 0.708 – 3.307 1.836 1.092 – 3.086
Expected BP rise (versus less than the expected rate) 0.71 0.347 – 1.454 0.904 0.548 – 1.493
NIDD = neurodevelopmental impairment or developmental delay; BP = blood pressure
*
one minute Apgar score ≤ 3, initial hematocrit ≤ 30%) any pH < 7.10 in the first 24 hours, a positive blood culture drawn within 72 hours of birth, 
or delivery room chest compressions
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